Q-omics provides the consensus-scored RNF146 profile across patient tissues and cancer cell-line models. RNF146 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RNF146 is differentially expressed in 10, with the highest sampling consensus in LUSC. Additionally, RNF146 protein abundance shows 25,263 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, LUSC, and LUAD as cancer lineages where RNF146 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNF146 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNF146 survival associations across molecular data types. RNF146 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNF146 RNA expression–survival associations across cancer types. High RNF146 expression shows unfavorable associations in DLBC and OV, but favorable associations in KIRC, LGG, SKCM and CHOL. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RNF146 RNA expression.
This table summarizes RNF146 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 8. The strongest signals are observed in LUSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for RNF146. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNF146 shows lower tumor expression in LUSC, KICH, LUAD, UCEC and BRCA and higher tumor expression in CHOL. The LUSC box plot shows higher RNF146 RNA expression in normal versus tumor tissue (log2 FC = −0.906, t-test p < 0.001).
This table shows molecular features associated with RNF146 in patient tissues and cancer cell lines. In patient samples, RNF146 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, RNF146 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
